CD274 and non-small cell lung carcinoma: For example, oleclumab, a first-in-human anti-CD73 mAb, in combination with anti-PD-L1 durvalumab, showed an ORR of 2.4%, 4.8%, and 9.5% in the pancreatic and NSCLC expansion cohorts of the phase I trial (NCT02503774) [190].